Seroepidemiological Study of Novel Coronavirus Disease (COVID-19) in Tehran, Iran

Q4 Medicine
Z. Tabanejad, S. Darvish, Z. Borjian Boroujeni, Seyed Saeed Asadi, Morteza Mesri, O. Raiesi, M. Getso, M. Zareei
{"title":"Seroepidemiological Study of Novel Coronavirus Disease (COVID-19) in Tehran, Iran","authors":"Z. Tabanejad, S. Darvish, Z. Borjian Boroujeni, Seyed Saeed Asadi, Morteza Mesri, O. Raiesi, M. Getso, M. Zareei","doi":"10.52547/iem.7.2.121","DOIUrl":null,"url":null,"abstract":"Backgrounds: A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to all countries of the world, including Iran. Although anti-SARS-CoV-2 antibodies may be identified in patients using immunological methods with sufficient sensitivity and specificity, the conclusive diagnosis of the disease is made using the molecular RT-PCR method. A population-based seroepidemiological survey was conducted to quantify the proportion of the exposed population with SARS-CoV-2 antibodies and evaluate whether the antibodies are a marker of total or partial immunity compared to the population that remains susceptible to the virus. Material & Methods: This cross-sectional study was conducted to investigate the seroprevalence of COVID-19 in Valiasr, Sajad, and Ghaem hospitals in Tehran, the capital of Iran, from April to the end of October 2020. Clotted and heparinized blood specimens (2mL) were collected from the patients. The serum and plasma were separated and stored at −80 °C until use. Anti-SARS-CoV-2 IgG and IgM antibodies were examined in the serum samples of 1375 in-patients admitted to the hospitals using ELISA kits. The obtained data were analyzed using SPSS software Ver.22.0 by employing statistical tests such as Chi-square and Fisher’s exact tests. A p-value <.05 was considered as significant. Findings: In total, 1375 participants were enrolled in this study, and SARS‐CoV‐2 antibodies were detected in 291 patients using IgM‐IgG antibody assay. Among the seropositive patients studied, 187 were male (64.3%), and 104 were female (35.7%) (p<.05). The mean age of the patients was 49±8.4 years;the majority of whom (27%) were in the age group of 31-40 years. Also, the lowest frequency of infected cases was related to the age group of 1-10 years (p <.05). The seroprevalence of SARS‐CoV‐2 IgM or IgG antibodies was determined to be 21.2%. Diabetes mellitus was the most common underlying disease among SARS‐CoV‐2 patients [p=.05;Odd Ratio=1.61(0.90-2.91)]. Conclusion: The use of conventional serological assays, such as the enzyme-linked immunoassay (ELISA), for detecting specific IgM and IgG antibodies in SARS‐CoV‐2 patients has a high-throughput advantage while minimizing false-negative results obtained using the RT-PCR method. In this study, the seroprevalence of SARS-CoV-2 antibodies was determined to be 21%. Control of diabetes, among other influential factors, plays an important role in the management and control of COVID-19. © 2021, TMU Press.","PeriodicalId":34545,"journal":{"name":"Infection Epidemiology and Microbiology","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Epidemiology and Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52547/iem.7.2.121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Backgrounds: A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to all countries of the world, including Iran. Although anti-SARS-CoV-2 antibodies may be identified in patients using immunological methods with sufficient sensitivity and specificity, the conclusive diagnosis of the disease is made using the molecular RT-PCR method. A population-based seroepidemiological survey was conducted to quantify the proportion of the exposed population with SARS-CoV-2 antibodies and evaluate whether the antibodies are a marker of total or partial immunity compared to the population that remains susceptible to the virus. Material & Methods: This cross-sectional study was conducted to investigate the seroprevalence of COVID-19 in Valiasr, Sajad, and Ghaem hospitals in Tehran, the capital of Iran, from April to the end of October 2020. Clotted and heparinized blood specimens (2mL) were collected from the patients. The serum and plasma were separated and stored at −80 °C until use. Anti-SARS-CoV-2 IgG and IgM antibodies were examined in the serum samples of 1375 in-patients admitted to the hospitals using ELISA kits. The obtained data were analyzed using SPSS software Ver.22.0 by employing statistical tests such as Chi-square and Fisher’s exact tests. A p-value <.05 was considered as significant. Findings: In total, 1375 participants were enrolled in this study, and SARS‐CoV‐2 antibodies were detected in 291 patients using IgM‐IgG antibody assay. Among the seropositive patients studied, 187 were male (64.3%), and 104 were female (35.7%) (p<.05). The mean age of the patients was 49±8.4 years;the majority of whom (27%) were in the age group of 31-40 years. Also, the lowest frequency of infected cases was related to the age group of 1-10 years (p <.05). The seroprevalence of SARS‐CoV‐2 IgM or IgG antibodies was determined to be 21.2%. Diabetes mellitus was the most common underlying disease among SARS‐CoV‐2 patients [p=.05;Odd Ratio=1.61(0.90-2.91)]. Conclusion: The use of conventional serological assays, such as the enzyme-linked immunoassay (ELISA), for detecting specific IgM and IgG antibodies in SARS‐CoV‐2 patients has a high-throughput advantage while minimizing false-negative results obtained using the RT-PCR method. In this study, the seroprevalence of SARS-CoV-2 antibodies was determined to be 21%. Control of diabetes, among other influential factors, plays an important role in the management and control of COVID-19. © 2021, TMU Press.
伊朗德黑兰地区新型冠状病毒病(COVID-19)血清流行病学研究
背景:一种新型严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)现已蔓延到包括伊朗在内的世界所有国家。尽管使用具有足够敏感性和特异性的免疫学方法可以在患者中鉴定出抗sars - cov -2抗体,但对该疾病的结论性诊断仍使用分子RT-PCR方法。开展了一项基于人群的血清流行病学调查,以量化携带SARS-CoV-2抗体的暴露人群的比例,并评估与病毒易感人群相比,抗体是完全免疫还是部分免疫的标志。材料与方法:本横断面研究旨在调查2020年4月至10月底伊朗首都德黑兰Valiasr、Sajad和Ghaem医院COVID-19的血清阳性率。采集患者凝血和肝素化血标本(2mL)。分离血清和血浆,在- 80℃保存待用。采用ELISA试剂盒检测1375例住院患者血清中抗sars - cov -2 IgG和IgM抗体。所得数据采用SPSS Ver.22.0软件进行分析,采用卡方检验、Fisher精确检验等统计检验。p值<。0.05为显著性。研究结果:共有1375名受试者参加了这项研究,使用IgM‐IgG抗体测定法在291例患者中检测到SARS‐CoV‐2抗体。血清阳性患者中男性187例(64.3%),女性104例(35.7%),差异有统计学意义(p< 0.05)。患者平均年龄49±8.4岁,31 ~ 40岁年龄组占比最大(27%)。1 ~ 10岁年龄组感染病例发生率最低(p < 0.05)。血清SARS - CoV - 2 IgM或IgG抗体阳性率为21.2%。糖尿病是SARS - CoV -2患者最常见的基础疾病[p= 0.05;奇比=1.61(0.90-2.91)]。结论:使用传统的血清学方法,如酶联免疫分析法(ELISA)检测SARS - CoV - 2患者的特异性IgM和IgG抗体具有高通量优势,同时最大限度地减少了RT-PCR方法获得的假阴性结果。在本研究中,SARS-CoV-2抗体的血清阳性率测定为21%。除其他影响因素外,糖尿病的控制在COVID-19的管理和控制中起着重要作用。©2021,TMU出版社。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
20
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信